➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Medtronic
AstraZeneca
Dow
McKinsey

Last Updated: June 14, 2021

DrugPatentWatch Database Preview

Drugs in Development Information for Cenicriviroc


Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Cenicriviroc?

Cenicriviroc is an investigational drug.

There have been 16 clinical trials for Cenicriviroc. The most recent clinical trial was a Phase 2 trial, which was initiated on April 20th 2017.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Cirrhosis. The leading clinical trial sponsors are Tobira Therapeutics, Inc., Allergan, and University of California, San Francisco.

There are two hundred and sixty-three US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Cenicriviroc
TitleSponsorPhase
Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIVAllergan, plcPhase 2
Study to Evaluate the Effects of Cenicriviroc Mesylate on Arterial Inflammation in People Living With HIVNational Institute of Allergy and Infectious Diseases (NIAID)Phase 2
Immune Modulators for Treating COVID-19Biomedical Advanced Research and Development AuthorityPhase 2

See all Cenicriviroc clinical trials

Clinical Trial Summary for Cenicriviroc

Top disease conditions for Cenicriviroc
Top clinical trial sponsors for Cenicriviroc

See all Cenicriviroc clinical trials

US Patents for Cenicriviroc

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cenicriviroc   Get Started Free Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections EMORY UNIVERSITY (Atlanta, GA)   Get Started Free
Cenicriviroc   Get Started Free Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the human immunodeficiency virus YALE UNIVERSITY (New Haven, CT)   Get Started Free
Cenicriviroc   Get Started Free Inhibitors of human immunodeficiency virus replication ViiV HEALTHCARE UK (NO. 5) LIMITED (Brentford, Middlesex, GB)   Get Started Free
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cenicriviroc

Drugname Country Document Number Estimated Expiration Related US Patent
Cenicriviroc Australia AU2012345732 2031-11-30   Get Started Free
Cenicriviroc Australia AU2016244212 2031-11-30   Get Started Free
Cenicriviroc Brazil BR112014013224 2031-11-30   Get Started Free
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
Baxter
Merck
McKesson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.